Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy

Agency reinterprets definition of "first applicant" and applies "failure to market" forfeiture provision of MMA; court halts sales of Dr. Reddy's generic.

FDABldg1ExteriorWithCircle_1200x675

The US FDA has clarified when sponsors are eligible for 180-day marketing exclusivity in a letter to applicants of abbreviated new drug applications for generic versions of Indivior PLC's Suboxone (buprenorphine/naloxone) sublingual film.

Specifically, the agency provided a new definition of "first applicant," whereby a sponsor does not lose this status by failing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership